"1"^^ . . "1"^^ . "\u010Cl\u00E1nek stru\u010Dn\u011B shrnuje nov\u00E9 poznatky o c\u00EDlov\u00FDch hodnot\u00E1ch krevn\u00EDho tlaku a \u00FA\u010Dinnosti nefarmakologick\u00FDch opat\u0159en\u00ED v l\u00E9\u010Db\u011B hypertenze. Jsou diskutov\u00E1ny v\u00FDhody a \u00FA\u010Dinnost kombina\u010Dn\u00ED l\u00E9\u010Dby hypertenze a mo\u017Enosti pou\u017Eit\u00ED fixn\u00EDxh dvojkombinac\u00ED a trojkombinac\u00ED. V z\u00E1v\u011Bru uv\u00E1d\u00EDme nov\u00E9 mo\u017Enosti l\u00E9\u010Dby rezistentn\u00ED hypertenze, kter\u00FDmi jsou nap\u0159\u00EDklad katetriza\u010Dn\u00ED ren\u00E1ln\u00ED denervace nebo vyu\u017Eit\u00ED spironolaktonu." . . . . . . "renal denervation; resistant hypertension; fixed combinations; combination treatment; non-pharmacologic interventions; treatment; hypertension"@en . "CZ - \u010Cesk\u00E1 republika" . . "What is new in the hypertension treatment?"@en . "4" . . . . "The article summarizes new information about target blood rssure values and about the effectiveness of non-pharmacologic interventions in the treatment of hypertension. Advantages and effectiveness of combination antihypertensive therapy and available fixed combinations of two or three drugs are discussed. The authors also mention new options in the treatment of resistant hypertension such as catheter-based renal denervation or use of spironolactone."@en . "190711" . "12" . "1212-9445" . "RIV/61989592:15110/11:10224090!RIV12-MSM-15110___" . "Co je nov\u00E9ho v l\u00E9\u010Db\u011B hypertenze"@cs . "15110" . "What is new in the hypertension treatment?"@en . "Medic\u00EDna po promoci" . "Co je nov\u00E9ho v l\u00E9\u010Db\u011B hypertenze" . . "[482E0BDCB82A]" . . "4"^^ . "I" . "Co je nov\u00E9ho v l\u00E9\u010Db\u011B hypertenze"@cs . . . . "RIV/61989592:15110/11:10224090" . . . "Co je nov\u00E9ho v l\u00E9\u010Db\u011B hypertenze" . . "V\u00E1clav\u00EDk, Jan" . . "\u010Cl\u00E1nek stru\u010Dn\u011B shrnuje nov\u00E9 poznatky o c\u00EDlov\u00FDch hodnot\u00E1ch krevn\u00EDho tlaku a \u00FA\u010Dinnosti nefarmakologick\u00FDch opat\u0159en\u00ED v l\u00E9\u010Db\u011B hypertenze. Jsou diskutov\u00E1ny v\u00FDhody a \u00FA\u010Dinnost kombina\u010Dn\u00ED l\u00E9\u010Dby hypertenze a mo\u017Enosti pou\u017Eit\u00ED fixn\u00EDxh dvojkombinac\u00ED a trojkombinac\u00ED. V z\u00E1v\u011Bru uv\u00E1d\u00EDme nov\u00E9 mo\u017Enosti l\u00E9\u010Dby rezistentn\u00ED hypertenze, kter\u00FDmi jsou nap\u0159\u00EDklad katetriza\u010Dn\u00ED ren\u00E1ln\u00ED denervace nebo vyu\u017Eit\u00ED spironolaktonu."@cs .